SPRINGDALE, Ark.--(BUSINESS WIRE)--NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced it has raised $22.5 million in Series B financing. Led by DigitalDx Ventures, with notable investors including the Labcorp Venture Fund and Kompass Kapital Management, this oversubscribed funding round will be used to drive the commercialization of at-home diagnostic tests, continue developing new diagnostic innovations, expand the pipeline of tests, and support strategic hiring initiatives..

阿肯色州斯普林代尔市。-（商业新闻短讯）--NOWDiagnostics，Inc.（NOWDx），一家非处方药（OTC）和即时护理（POC）诊断测试的开发商，今天宣布已筹集2250万美元的B系列融资。在DigitalDx Ventures的带领下，包括Labcorp风险基金和Kompass Kapital Management在内的著名投资者，这轮超额认购的资金将用于推动国内诊断测试的商业化，继续开发新的诊断创新，扩大测试渠道，并支持战略招聘计划。

NOWDx was founded to provide accurate, accessible, and affordable diagnostic testing for at-home use. The company’s First To Know® Syphilis OTC test is undergoing De Novo review by the U.S. Food and Drug Administration (FDA). First To Know® has the potential to be the first and only rapid syphilis test in the U.S.

NOWDx的成立旨在为家庭使用提供准确，可访问且价格合理的诊断测试。该公司的首个Know®梅毒OTC测试正在接受美国食品和药物管理局（FDA）的从头审查。First To Know®有可能成为美国第一个也是唯一一个快速梅毒检测方法。

that provides an at-home result in minutes. In addition to syphilis, NOWDx has over 30 diagnostic tests in the clinical research pipeline that have the potential to provide accurate results in minutes..

这将在几分钟内提供一个在家的结果。除了梅毒，NOWDx在临床研究管道中还有30多项诊断测试，有可能在几分钟内提供准确的结果。

'We are thrilled to have the strong support of our investor group, which spans both new and returning participants,' said Rob Weigle, CEO of NOWDx. “This oversubscribed round is a testament to our technology platform and mission. Testing is one of the most crucial tools in preventing the spread of infection and ensuring the well-being of public health.

NOWDx首席执行官罗伯·威格尔（RobWeigle）说，我们很高兴能得到投资者集团的大力支持，该集团涵盖了新参与者和回归参与者。“这一轮超额认购证明了我们的技术平台和使命。测试是预防感染传播和确保公共卫生福祉的最关键工具之一。

We are committed to making accurate, easy-to-use, and affordable at-home tests available to all.'.

我们致力于为所有人提供准确、易于使用且价格合理的家庭测试。”

The patented technology platform that powers NOWDx’s products represents a significant advancement in rapid diagnostics. With over 75 patents issued and pending, the company’s innovative approach allows virtually any immunological assay to be accurately performed in one step using a small amount of capillary blood, yielding results in minutes.

为NOWDx产品提供动力的专利技术平台代表了快速诊断领域的重大进步。该公司已发布并正在申请75多项专利，其创新方法几乎可以使用少量毛细血管血一步准确地进行任何免疫学检测，几分钟即可产生结果。

Their platforms also include saliva and plasma test technologies, enabling next-generation rapid testing at home without needing a blood draw or throat swab. These innovations enhance accessibility and ensure that individuals can quickly and confidently take the necessary steps for their health and well-being in the privacy of their homes..

他们的平台还包括唾液和血浆检测技术，可以在家中进行下一代快速检测，而无需抽血或咽拭子。这些创新提高了可访问性，并确保个人能够在家中的隐私中快速而自信地采取必要的措施，以确保自己的健康和福祉。

'This investment in NOWDx underscores our confidence in their visionary leadership and commitment to providing diagnostic innovations that could save lives,' said Seth Auld, Vice President of Portfolio Management & Investment Originations at Kompass Kapital Management. 'The importance of at-home testing cannot be overstated, as it enhances access to essential personal health information quickly to make more informed decisions for one’s health.

Kompass Kapital Management负责投资组合管理和投资发起的副总裁赛斯·奥尔德（SethAuld）说，对NOWDx的这项投资突显了我们对他们富有远见的领导能力的信心，以及对提供能够挽救生命的诊断创新的承诺在家测试的重要性怎么强调也不过分，因为它可以快速获得基本的个人健康信息，从而为一个人的健康做出更明智的决定。

We look forward to witnessing the impact of their pioneering technology on health outcomes and the subsequent impact this technology will enable.'.

我们期待着看到他们的开创性技术对健康结果的影响，以及这项技术将产生的后续影响。”

About NOWDiagnostics (NOWDx)

关于NOWDiagnostics（NOWDx）

NOWDx develops and manufactures over-the-counter (OTC) and point-of-care (POC) diagnostic tests. Its patented approach enables virtually any immunological assay to be accurately performed onsite in one step using a small amount of capillary blood, yielding results in minutes. With over 75 patents issued and pending, NOWDx’s First To Know® and ADEXUSDx® product lines are available in markets worldwide.

NOWDx开发和制造非处方药（OTC）和即时护理（POC）诊断测试。。NOWDx的首个Know®和ADEXUSDx®产品线已在全球市场上推出，已发布并正在申请75多项专利。

Founded in 2013, with headquarters and manufacturing in Springdale, Arkansas, NOWDx envisions a world where people have greater access to in-home testing with results in minutes. The company is committed to changing healthcare by providing accessible, affordable, and accurate testing for all. Please visit nowdx.com for more information..

NOWDx成立于2013年，总部和生产基地位于阿肯色州的斯普林代尔，它设想了一个世界，在这个世界上，人们可以在几分钟内获得更多的家庭测试结果。该公司致力于通过为所有人提供可访问、价格合理且准确的测试来改变医疗保健。有关更多信息，请访问nowdx.com。

About Labcorp

关于Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities.

Labcorp（纽约证券交易所代码：LH）是创新和综合实验室服务的全球领导者，可帮助医生、医院、制药公司、研究人员和患者做出明确而自信的决定。我们通过无与伦比的诊断和药物开发实验室能力，为改善健康和改善生活提供见解和先进科学。

The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com..

该公司拥有67000多名员工，为大约100个国家的客户提供服务，为2023年FDA批准的84%的新药和治疗产品提供支持，并为世界各地的患者进行了超过6亿次测试。有关我们的更多信息，请访问www.Labcorp.com。

DigitalDx Ventures is a woman-owned Venture Capital fund in Silicon Valley supporting companies that diagnose illness earlier, less invasively, more accurately and less expensively enabled by artificial intelligence and data. The Fund is committed to producing a triple bottom line: superior financial returns, diversity and access to healthcare for all.

DigitalDx Ventures是硅谷的一家女性拥有的风险投资基金，支持通过人工智能和数据更早、更具侵略性、更准确和更便宜地诊断疾病的公司。该基金致力于创造三重底线：卓越的财务回报、多样性和人人享有医疗保健。

There are currently 8 companies in the portfolio providing game changing diagnostics in Alzheimer's diagnosis, kidney health, breast cancer, mental health, maternal health, patient monitoring and multi cancer screening. For more information, visit https://www.digitaldxventures.com/.

目前，该组合中有8家公司在阿尔茨海默病诊断，肾脏健康，乳腺癌，心理健康，孕产妇健康，患者监测和多种癌症筛查方面提供改变游戏规则的诊断。有关更多信息，请访问https://www.digitaldxventures.com/.

About Kompass Kapital Management

关于Kompass Kapital Management

Kompass Kapital Management (KKM) is a diversified private equity group committed to creating long-term value by providing resources beyond capital. With a portfolio that spans multiple industries and geographies, KKM partners with entrepreneurs who share their values and vision. For more information, visit https://kompasskapital.com/.

Kompass Kapital Management（KKM）是一家多元化的私人股本集团，致力于通过提供资本以外的资源来创造长期价值。KKM拥有跨越多个行业和地区的投资组合，与分享价值观和愿景的企业家合作。有关更多信息，请访问https://kompasskapital.com/.